A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

NCT00577278 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Graft Versus Host Disease
Leukemia
Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: fludarabine phosphate
DRUG: melphalan
DRUG: sirolimus
DRUG: tacrolimus
PROCEDURE: allogeneic hematopoietic stem cell transplantation
RADIATION: indium In 111 ibritumomab tiuxetan
RADIATION: yttrium Y 90 ibritumomab tiuxetan
OTHER: laboratory biomarker analysis

Sponsor

City of Hope Medical Center

Collaborators

[object Object]